These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 37428429)

  • 21. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study.
    Jankowska EA; Kirwan BA; Kosiborod M; Butler J; Anker SD; McDonagh T; Dorobantu M; Drozdz J; Filippatos G; Keren A; Khintibidze I; Kragten H; Martinez FA; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parkhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Lewis BS; Comin-Colet J; von Haehling S; Cohen-Solal A; Danchin N; Doehner W; Dargie HJ; Motro M; Friede T; Fabien V; Dorigotti F; Pocock S; Ponikowski P
    Eur Heart J; 2021 Aug; 42(31):3011-3020. PubMed ID: 34080008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis.
    Anker SD; Kirwan BA; van Veldhuisen DJ; Filippatos G; Comin-Colet J; Ruschitzka F; Lüscher TF; Arutyunov GP; Motro M; Mori C; Roubert B; Pocock SJ; Ponikowski P
    Eur J Heart Fail; 2018 Jan; 20(1):125-133. PubMed ID: 28436136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Iron Deficiency Treatment in Patients with Heart Failure.
    Jankowska EA; Drozd M; Ponikowski P
    Handb Exp Pharmacol; 2017; 243():561-576. PubMed ID: 28405775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Responder analysis for improvement in 6-min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency.
    Anker SD; Ponikowski P; Khan MS; Friede T; Jankowska EA; Fabien V; Goehring UM; Metra M; Piña IL; Coats AJS; Rosano G; Dorigotti F; Comin-Colet J; Van Veldhuisen DJ; Filippatos GS; Butler J
    Eur J Heart Fail; 2022 May; 24(5):833-842. PubMed ID: 35334136
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: A Bayesian meta-analysis.
    Anker SD; Khan MS; Butler J; von Haehling S; Jankowska EA; Ponikowski P; Friede T
    Eur J Heart Fail; 2023 Jul; 25(7):1080-1090. PubMed ID: 37062867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is Correction of Iron Deficiency a New Addition to the Treatment of the Heart Failure?
    Silverberg DS; Wexler D; Schwartz D
    Int J Mol Sci; 2015 Jun; 16(6):14056-74. PubMed ID: 26096008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anaemia, iron deficiency and heart failure in 2020: facts and numbers.
    Chopra VK; Anker SD
    ESC Heart Fail; 2020 Oct; 7(5):2007-2011. PubMed ID: 32602663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iron Therapy in Patients with Heart Failure and Iron Deficiency: Review of Iron Preparations for Practitioners.
    Drozd M; Jankowska EA; Banasiak W; Ponikowski P
    Am J Cardiovasc Drugs; 2017 Jun; 17(3):183-201. PubMed ID: 28039585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic review and meta-analysis of intravenous iron-carbohydrate complexes in HFrEF patients with iron deficiency.
    Sindone A; Doehner W; Comin-Colet J
    ESC Heart Fail; 2023 Feb; 10(1):44-56. PubMed ID: 36178088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Iron deficiency as therapeutic target in heart failure: a translational approach.
    Bakogiannis C; Briasoulis A; Mouselimis D; Tsarouchas A; Papageorgiou N; Papadopoulos C; Fragakis N; Vassilikos V
    Heart Fail Rev; 2020 Mar; 25(2):173-182. PubMed ID: 31230175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study.
    Comin-Colet J; Lainscak M; Dickstein K; Filippatos GS; Johnson P; Lüscher TF; Mori C; Willenheimer R; Ponikowski P; Anker SD
    Eur Heart J; 2013 Jan; 34(1):30-8. PubMed ID: 22297124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Iron deficiency testing and treatment in heart failure: the eyes are useless when the mind is blind.
    Miñana G; Bayés-Genís A; Núñez J
    Eur J Heart Fail; 2021 Nov; 23(11):1855-1857. PubMed ID: 34655260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Indirect comparison between ferric carboxymaltose and oral iron replacement in heart failure with reduced ejection fraction: a network meta-analysis.
    Sciatti E; Nesti U; Di Lenarda A
    Monaldi Arch Chest Dis; 2021 Mar; 91(3):. PubMed ID: 33794590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iron deficiency and cardiovascular disease.
    Savarese G; von Haehling S; Butler J; Cleland JGF; Ponikowski P; Anker SD
    Eur Heart J; 2023 Jan; 44(1):14-27. PubMed ID: 36282723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ferric carboxymaltose for iron deficiency in patients with heart failure: a systematic review and meta-analysis.
    Rangwala BS; Zuhair V; Mustafa MS; Mussarat A; Khan AW; Danish F; Fatima Zaidi SM; Rehman FU; Shafique MA
    Future Sci OA; 2024 Dec; 10(1):2367956. PubMed ID: 38982752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Iron deficiency in patients with acute and chronic heart failure - a simple algoritm].
    Lindgren S; Hjortswang H; Moum B; Vasko P; H Lund L
    Lakartidningen; 2022 Sep; 119():. PubMed ID: 36149233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iron therapy and severe arrhythmias in HFrEF: rationale, study design, and baseline results of the RESAFE-HF trial.
    Bakogiannis C; Mouselimis D; Tsarouchas A; Papadopoulos CE; Theofillogiannakos EK; Lechat E; Antoniadis AP; Pagourelias ED; Kelemanis I; Tzikas S; Fragakis N; Efthimiadis GK; Karamitsos TD; Doumas M; Vassilikos VP
    ESC Heart Fail; 2023 Apr; 10(2):1184-1192. PubMed ID: 36647691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Usefulness of Iron Deficiency Correction in Management of Patients With Heart Failure [from the Registry Analysis of Iron Deficiency-Heart Failure (RAID-HF) Registry].
    Wienbergen H; Pfister O; Hochadel M; Michel S; Bruder O; Remppis BA; Maeder MT; Strasser R; von Scheidt W; Pauschinger M; Senges J; Hambrecht R;
    Am J Cardiol; 2016 Dec; 118(12):1875-1880. PubMed ID: 27756479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis.
    Gutzwiller FS; Pfeil AM; Comin-Colet J; Ponikowski P; Filippatos G; Mori C; Braunhofer PG; Szucs TD; Schwenkglenks M; Anker SD
    Int J Cardiol; 2013 Oct; 168(4):3878-83. PubMed ID: 23870642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.